Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 8/20 | 0.48 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | P2RY11 | Q96G91 | 2/20 | 0.45 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.45 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.45 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.45 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.45 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.45 |
| ▸ | AHCY | P23526 | 3/20 | 0.44 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.43 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26289790 | 0.89 | P2RY1 (0.50) | P2RY1P2RY2CA5AP2RY11ENPP1 | |
| SCHEMBL19211131 | 0.86 | P2RY1 (0.48) | P2RY1P2RY2CA5AP2RY11ENPP1 | |
| SCHEMBL30590475 | 0.86 | P2RY1 (0.48) | P2RY1P2RY2CA5AP2RY11ENPP1 | |
| SCHEMBL26289786 | 0.85 | CA5A (0.47) | P2RY1P2RY2CA5AP2RY11ENPP1 | |
| SCHEMBL16373853 | 0.85 | POLB (0.54) | P2RY1P2RY2P2RY6NT5E | |
| SCHEMBL25565236 | 0.83 | P2RY1 (0.48) | P2RY1P2RY2CA5AP2RY11ENPP1 | |
| SCHEMBL25565235 | 0.82 | CA5A (0.48) | P2RY1P2RY2CA5AP2RY11ENPP1 | |
| SCHEMBL25395433 | 0.82 | AHCY (0.52) | CA5AAHCYNT5E | |
| SCHEMBL26135243 | 0.82 | AHCY (0.52) | CA5AAHCYNT5E | |
| SCHEMBL16374061 | 0.81 | P2RY1 (0.58) | P2RY1P2RY2P2RY11ENPP1P2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215039-A1 | NUCLEOSIDES FOR TREATING CANCER | PRIMEFOUR THERAPEUTICS INC (US) | 2025-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250215039-A1 | NUCLEOSIDES FOR TREATING CANCER | UNG, OGG1, NTPCR | P2RY1 2444/4885P2RY2 2956/4885CA5A 1560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.